Clinical Trial Resource Center


Clinical Trial Resource Center

FDA Approved Drugs » Therapeutic Areas

View By:Year | Company | Conditions | Therapeutic Areas | Drug Names

FDA Approved Drugs by Therapeutic Area

Search by therapeutic area for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Click on an area below to view the complete list of drugs in that category or review descriptions for our therapeutic area list to assist you in your search.

Find out more about the types of drugs included in this listing.

FDA Approved Drugs for Dermatology

Drugs Approved in 2014

Dalvance (dalbavancin); Durata Therapeutics; For the treatment of acute bacterial skin and skin structure infections, Approved May 2014

Jublia (efinaconazole) 10% topical gel; Valeant Pharmaceuticals; For the treatment of onychomycosis of the toenails, Approved June 2014

Kerydin (tavaborole); Anacor; For the treatment of onychomycosis of the toenails, Approved July 2014

Sivextro (tedizolid phosphate) ; Cubist Pharmaceuticals; For the treatment of acute bacterial skin and skin structure infections, Approved June 2014

Drugs Approved in 2013

Luzu (luliconazole) Cream 1%; Valeant Pharmaceuticals; For the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis, November of 2013

Mekinist (trametinib); GlaxoSmithKline; For the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, Approved May of 2013

Mirvaso (brimonidine); Galderma Labs; For the treatment of facial erythema of rosacea, Approved August 2013

Sitavig (acyclovir) buccal tablets; BioAlliance Pharma; For the treatment of recurrent herpes labialis in adults, Approved April 2013

Tafinlar (dabrafenib); GlaxoSmithKline; For the treatment of unresectable or metastatic melanoma with BRAF V600E mutation, Approved May 2013

Valchlor (mechlorethamine) gel; Ceptaris Therapeutics; For the treatment of Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma, Approved August 2013

Varithena (polidocanol injectable foam); BTG plc; For the treatment of varicose veins, November 2013

Drugs Approved in 2012

Erivedge (vismodegib); Genentech; For the treatment of basal cell carcinoma, Approved January 2012

Horizant (gabapentin enacarbil); GlaxoSmithKline; For the treatment of postherpetic neuralgia, Approved June 2012

Picato (ingenol mebutate) gel; LEO Pharma; For the treatment of actinic keratosis, Approved January 2012

Sklice (ivermectin) lotion; Sanofi Pasteur; For the treatment of head lice, Approved February 2012

Drugs Approved in 2011

Firazyr (icatibant); Shire Pharmaceuticals; For the treatment of acute attacks of hereditary angioedema, Approved August of 2011

Gralise (gabapentin); Abbott Laboratories; For the treatment of postherpetic neuralgia, Approved February 2011

laViv (azficel-T); Fibrocell Science; For the improvement of nasolabial fold wrinkles in adults, Approved June 2011

Sylatron (peginterferon alfa-2b); Merck; For the treatment of melanoma, Approved April 2011

Yervoy (ipilimumab); Bristol-Myers Squibb; For the treatment of metastatic melanoma, Approved March 2011

Zelboraf (vemurafenib); Roche; For the treatment of BRAF + melanoma, Approved August of 2011

Drugs Approved in 2010

Teflaro (ceftaroline fosamil); Cerexa; For the treatment of bacterial skin infections and bacterial pneumonia, November 2010

Veltin (clindamycin phosphate and tretinoin); Stiefel; For the treatment of acne vulgaris, Approved July 2010

Zyclara (imiquimod); Graceway; For the treatment of actinic keratoses of the face and scalp, Approved March 2010

Drugs Approved in 2009

Stelara (ustekinumab); Centocor Ortho Biotech; For the treatment of plaque psoriasis, Approved September 2009

Vibativ (telavancin); Theravance; For the treatment of complicated skin and skin structure infections, Approved September 2009

Drugs Approved in 2007

Altabax (retapamulin); GlaxoSmithKline; For the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes, Approved April 2007

Extina (ketoconazole); Stiefel; For the treatment of seborrheic dermatitis, Approved June 2007

Xyzal (levocetirizine dihydrochloride); UCB; For the treatment of seasonal and perennial allergic rhinitis and urticaria, Approved May 2007

Drugs Approved in 2006

Desonate (desonide); Dow Pharm; For the treatment of atopic dermatitis, Approved October 2006

Verdeso (desonide); Connetics Corporation; For the treatment of atopic dermatitis, Approved September 2006

Drugs Approved in 2005

Tygacil (tigecycline); Wyeth; For the treatment of complicated skin and skin structure and intra-abdominal infections and bacterial pneumonia, Approved 2005

Drugs Approved in 2003

Amevive (alefacept); Biogen IDEC; For moderate to severe chronic plaque psoriasis., Approved January 2003

Finacea (azelaic acid) Gel, 15%; Berlex Laboratories; Gel formulation for the treatment of rosacea., January 2003

Drugs Approved in 2002

Botox Cosmetic (botulinum toxin type A); Allergan; For the temporary improvement in the appearance of glabellar lines (brow furrow), Approved April 2002

Drugs Approved in 2001

Elidel; Novartis; Topical cream for the treatment of atopic dermatitis, Approved December 2001

Estrostep (norethindrone acetate and ethinyl estradiol); Pfizer; For the treatment of moderate acne vulgaris, Approved July 2001

Finevin; Berlex Laboratories; Topical cream for the treatment of mild to moderate inflammatory acne vulgaris, Approved May 2001

Invanz; Merck; Once-daily injectable treatment for bacterial infections, Approved November 2001

Lamisil Solution, 1%; Novartis; Topical treatment for tinea (pityriasis) versicolor, althete's foot, jock itch, and ringworm, Approved March 2001

Drugs Approved in 2000

Benzamycin (erythromycin 3%-benzoyl peroxide 5% topical gel); Dermik Laboratories; For the topical treatment of acne vulgaris, Approved November 2000

Cefazolin and Dextrose USP; B Braun Medical; Respiratory tract infections, Approved July 2000

Chloraprep (chlorhexidine gluconate); MEDI FLEX HOSP PRODUCTS; For use as a patient preoperative skin preparation, Approved July 2000

Clindamycin phosphate topical gel; Target Research Associates; For once a day treatment of acne vulgaris, Approved November 2000

Lamisil (terbinafine hydrochloride) Solution, 1%; Novartis; For the treatment of athlete's foot, jock itch and ringworm, Approved March 2000

Protopic (tacrolimus) ointment; Fujisawa Healthcare; For short-term and intermittent long-term treatment of moderate to severe atopic dermatitis, Approved December 2000

Skin Exposure Reduction Paste Against Chemical Warfare Agents (SERPACWA); US Army Medical Research, Material Command; To reduce absorption of chemical warfare agents through the skin, Approved February 2000

Drugs Approved in 1999

Lamisil (terbinafine hydrochloride) Dermagel, 1%; Novartis; Treatment for tinea pedis (athlete's foot), Approved March 1999

Luxiq (betamethasone valerate) Foam; Connetics Corporation; Treatment for dermatoses of scalp, Approved June 1999

Drugs Approved in 1998

Dynabac; Sanofi-aventis; Treatment for acute bacterial exacerbations (chronic bronchitis and skin infections), Approved March 1998

Lustra; Medicis Pharmaceutical; Treatment for ultraviolet-induced skin discolorations, Approved January 1998

MetroLotion; Galderma Laboratories; Treatment of inflammatory papules and pustules of rosacea, Approved November 1998

Noritate; Dermik Laboratories; Treatment for rosacea, Approved January 1998

Salagen Tablets; MGI Pharma; Treatment for Sjogren's Syndrome, Approved February 1998

Sulfamylon; Mylan Laboratories; Treatment used to control bacterial infections on excised burn wounds, Approved June 1998

Thalomid; Celgene; Treatment for moderate to severe erythema nodosum leprosum (ENL), Approved July 1998

Drugs Approved in 1997

Avita Gel; Penederm; Treatment for acne, Approved January 1997

Bactroban Cream; SmithKline Beecham; Treatment for secondarily infected traumatic skin lesions, Approved December 1997

Clindamycin Phosphate Topical Solution USP 1%; Morton Grove Pharmaceuticals; Generic equivalent of CLEOCIN Topical Solution 1%, Approved July 1997

Condylox Gel 0.5% (pokofilox); Oclassen Pharmaceuticals; Treatment for external genital and perianal warts, Approved March 1997

Dermagraft-TC; Advanced Tissue Sciences; Treatment for partial-thickness and severe burns, Approved October 1997

Klaron (sodium sulfacet amide lotion ) Lotion, 10%; Dermik Laboratories; Treatment for adult acne, Approved February 1997

Mentax (1% butenafine HCl cream); Penederm; Treatment for athlete's foot, Approved December 1997

Mentax (1% butenafine HCl cream); Penederm; Treatment for tinea corporis (ringworm) and tinea cruris (groin fungus), Approved January 1997

Minoxidil Topical Solution 2% for Women; Alpharma; Generic equivalent of Rogaine, Approved April 1997

Omnicef; Warner-Lambert; Treatment against various bacterias, Approved December 1997

Ortho Tri-Cyclen Tablets (norgestimate/ethinyl estradiol); Ortho-McNeil Pharmaceutical; Treatment for acne in women seeking contraception, Approved January 1997

Propecia; Merck; Treatment for male baldness, Approved December 1997

REGRANEX (becaplermin) Gel; RW Johnson; Treatment for diabetic foot ulcers, Approved December 1997

Retin-A Micro (tretinoin gel) microsphere, 0.1%; Advanced Polymer Systems; Treatment for acne, Approved February 1997

Tazorac topical gel; Allergan; Treatment for Psoriasis, Acne Vulgaris, Approved June 1997

Drugs Approved in 1996

Differin (adapalene gel) Gel, 0.1%; Galderma Laboratories; Treatment for acne, Approved June 1996

Iamin; ProCyte; Gel wound dressing, Approved February 1996

Iontocaine; Iomed; Needle-free anesthetic, Approved May 1996

IvyBlock; EnviroDerm Pharmaceuticals; Treatment for poison ivy, poison oak, and poison sumac, Approved September 1996

Drugs Approved in 1995

Renova (tretinoin emollient cream); Johnson & Johnson; Treatment for facial wrinkles, brown spots, and surface roughness associated with chronic sun exposure, Approved December 1995